Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
NCT ID: NCT04127058
Last Updated: 2020-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
12 participants
INTERVENTIONAL
2019-10-07
2019-11-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
NCT04819776
Iloperidone in Mixed States of Bipolar Disorder
NCT02413918
Valproate Efficacy in Cocaine-Bipolar Comorbidity
NCT00240110
PET and MRI Brain Imaging of Bipolar Disorder
NCT01880957
Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder
NCT00563992
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CYP2D6 non-poor metabolizers
titrated up to 24 mg daily (12 mg b.i.d.)
Iloperidone
Oral Tablet
CYP2D6 poor metabolizers
titrated up to 12 mg daily (6 mg b.i.d.)
Iloperidone
Oral Tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iloperidone
Oral Tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with either schizophrenia or bipolar I disorder, manic or mixed type as per DSM-V criteria
* Symptomatically stable within the past two months
Exclusion Criteria
* Non-response to clozapine
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanda Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanda Investigational Site
Marlton, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VP-VYV-683-1004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.